+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030- Product Image
Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030- Product Image
New

Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 4118788
Description Jump to:

Gastroesophageal Reflux Disease Therapeutics Market Growth & Trends

The global gastroesophageal reflux disease therapeutics market size is anticipated to reach USD 5.77 billion by 2030. The market is projected to grow at a CAGR of 2.0% from 2025 to 2030. The growth is attributed to increasing prevalence of gastroesophageal reflux disease and other gastrointestinal diseases. Moreover, change in lifestyle and food habits, low success rates associated with GERD management devices and increasing demand for self-medication is further propelling the industry growth.

Increasing prevalence of gastroesophageal reflux and other gastric disorders is propelling the growth of the market. For instance, it is estimated that around 13.98% of total population is affected by GERD, which equals to around 1.03 billion people suffering from GERD globally. The rising incidence of the condition propels the need for proper treatment. Individuals using over-the-counter medication to treat unidentified problems may be at a higher risk. Untreated GERD condition not only increases uncomfortableness but may result in a number of additional medical issues.

Treatment of GERD generally includes lifestyle modification, surgical therapy, and medical therapy. Patients who do not respond to lifestyle changes receive a therapeutic intervention. Antacids, antisecretory drugs like PPI treatment or histamine (H2) receptor antagonists (H2RAs), and prokinetic drugs make up therapeutics. Famotidine and cimetidine are two H2RAs that have been licensed by the US Food and Drug Administration (FDA) and are currently offered over the counter in the US. Because of an unanticipated impurity in the active ingredient, the other H2RA that is frequently used, ranitidine, has been recalled due to a potential health risk or safety concern.

Furthermore, key players are focusing on incorporating gastroesophageal reflux disease therapeutics. For instance, in May 2022, Phathom Pharmaceuticals announced FDA approval for Vonoprazan, a NDA for the treatment of adults with all grades of erosive esophagitis and to provide healing and relief from heartburn. Moreover, in November 2022, JB Pharma launched RANRAFT, a novel formulation that helps in providing quick relief for acid reflux and heartburn.

Gastroesophageal Reflux Disease Therapeutics Market Report Highlights

  • Antacids segment dominated the gastroesophageal reflux disease treatment market in 2024 and is attributable to the rapid and quick relief offered by antacids, as they tend to counteract the acidity inside the stomach.
  • Untreated condition owing to unnecessary condition that leads to additional medical issues is propelling the demand for proper therapeutics.
  • Key players operating in the market are focusing on developing medications that helps in curbing the uncomfortable condition occurring through GERD.
  • North America held the largest market share which can be attributed to the increasing technological advancements in diagnostics technologies that facilitate rehabilitation of disabled patients.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Type
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Gastroesophageal Reflux Disease Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Gastroesophageal Reflux Disease Therapeutics Market: Drug Type Business Analysis
4.1. Drug Type Market Share, 2024 & 2030
4.2. Drug Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
4.4. Antacids
4.4.1. Antacids Market, 2018 - 2030 (USD Million)
4.5. H2 Receptor Blockers
4.5.1. H2 Receptor Blockers Market, 2018 - 2030 (USD Million)
4.6. Proton Pump Inhibitors (PPIs)
4.6.1. Proton Pump Inhibitors (PPIs) Market, 2018 - 2030 (USD Million)
4.7. Pro-kinetic Agents
4.7.1. Pro-kinetic Agents Market, 2018 - 2030 (USD Million)
Chapter 5. Gastroesophageal Reflux Disease Therapeutics Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2024 & 2030
5.2. Regional Market Dashboard
5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
5.4. North America
5.4.1. North America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
5.4.2. U.S.
5.4.2.1. Key Country Dynamics
5.4.2.2. Regulatory Framework
5.4.2.3. Competitive Insights
5.4.2.4. U.S. Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.3. Canada
5.4.3.1. Key Country Dynamics
5.4.3.2. Regulatory Framework
5.4.3.3. Competitive Insights
5.4.3.4. Canada Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.4. Mexico
5.4.4.1. Key Country Dynamics
5.4.4.2. Regulatory Framework
5.4.4.3. Competitive Insights
5.4.4.4. Mexico Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5. Europe
5.5.1. Europe Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
5.5.2. UK
5.5.2.1. Key Country Dynamics
5.5.2.2. Regulatory Framework
5.5.2.3. Competitive Insights
5.5.2.4. UK Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.3. Germany
5.5.3.1. Key Country Dynamics
5.5.3.2. Regulatory Framework
5.5.3.3. Competitive Insights
5.5.3.4. Germany Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.4. France
5.5.4.1. Key Country Dynamics
5.5.4.2. Regulatory Framework
5.5.4.3. Competitive Insights
5.5.4.4. France Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.5. Italy
5.5.5.1. Key Country Dynamics
5.5.5.2. Regulatory Framework
5.5.5.3. Competitive Insights
5.5.5.4. Italy Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.6. Spain
5.5.6.1. Key Country Dynamics
5.5.6.2. Regulatory Framework
5.5.6.3. Competitive Insights
5.5.6.4. Spain Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.7. Norway
5.5.7.1. Key Country Dynamics
5.5.7.2. Regulatory Framework
5.5.7.3. Competitive Insights
5.5.7.4. Norway Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.8. Denmark
5.5.8.1. Key Country Dynamics
5.5.8.2. Regulatory Framework
5.5.8.3. Competitive Insights
5.5.8.4. Denmark Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.9. Sweden
5.5.9.1. Key Country Dynamics
5.5.9.2. Regulatory Framework
5.5.9.3. Competitive Insights
5.5.9.4. Sweden Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6. Asia Pacific
5.6.1. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
5.6.2. Japan
5.6.2.1. Key Country Dynamics
5.6.2.2. Regulatory Framework
5.6.2.3. Competitive Insights
5.6.2.4. Japan Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.3. China
5.6.3.1. Key Country Dynamics
5.6.3.2. Regulatory Framework
5.6.3.3. Competitive Insights
5.6.3.4. China Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.4. India
5.6.4.1. Key Country Dynamics
5.6.4.2. Regulatory Framework
5.6.4.3. Competitive Insights
5.6.4.4. India Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.5. South Korea
5.6.5.1. Key Country Dynamics
5.6.5.2. Regulatory Framework
5.6.5.3. Competitive Insights
5.6.5.4. South Korea Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.6. Australia
5.6.6.1. Key Country Dynamics
5.6.6.2. Regulatory Framework
5.6.6.3. Competitive Insights
5.6.6.4. Australia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.7. Thailand
5.6.7.1. Key Country Dynamics
5.6.7.2. Regulatory Framework
5.6.7.3. Competitive Insights
5.6.7.4. Thailand Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.7. Latin America
5.7.1. Latin America Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
5.7.2. Brazil
5.7.2.1. Key Country Dynamics
5.7.2.2. Regulatory Framework
5.7.2.3. Competitive Insights
5.7.2.4. Brazil Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.7.3. Argentina
5.7.3.1. Key Country Dynamics
5.7.3.2. Regulatory Framework
5.7.3.3. Competitive Insights
5.7.3.4. Argentina Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.8. MEA
5.8.1. MEA Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
5.8.2. South Africa
5.8.2.1. Key Country Dynamics
5.8.2.2. Regulatory Framework
5.8.2.3. Competitive Insights
5.8.2.4. South Africa Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.8.3. Saudi Arabia
5.8.3.1. Key Country Dynamics
5.8.3.2. Regulatory Framework
5.8.3.3. Competitive Insights
5.8.3.4. Saudi Arabia Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.8.4. UAE
5.8.4.1. Key Country Dynamics
5.8.4.2. Regulatory Framework
5.8.4.3. Competitive Insights
5.8.4.4. UAE Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.8.5. Kuwait
5.8.5.1. Key Country Dynamics
5.8.5.2. Regulatory Framework
5.8.5.3. Competitive Insights
5.8.5.4. Kuwait Gastroesophageal Reflux Disease Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Participant Overview
6.2. Company Market Position Analysis
6.3. Company Categorization
6.4. Strategy Mapping
6.5. Company Profiles/Listing
6.5.1. AstraZeneca
6.5.1.1. Overview
6.5.1.2. Financial Performance
6.5.1.3. Product Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Eisai Co., Ltd.
6.5.2.1. Overview
6.5.2.2. Financial Performance
6.5.2.3. Product Benchmarking
6.5.2.4. Strategic Initiatives
6.5.3. GSK plc.
6.5.3.1. Overview
6.5.3.2. Financial Performance
6.5.3.3. Product Benchmarking
6.5.3.4. Strategic Initiatives
6.5.4. Takeda Pharmaceutical Company Limited
6.5.4.1. Overview
6.5.4.2. Financial Performance
6.5.4.3. Product Benchmarking
6.5.4.4. Strategic Initiatives
6.5.5. Ironwood
6.5.5.1. Overview
6.5.5.2. Financial Performance
6.5.5.3. Product Benchmarking
6.5.5.4. Strategic Initiatives
6.5.6. Johnson & Johnson Services, Inc.
6.5.6.1. Overview
6.5.6.2. Financial Performance
6.5.6.3. Product Benchmarking
6.5.6.4. Strategic Initiatives
6.5.7. SFJ Pharmaceuticals
6.5.7.1. Overview
6.5.7.2. Financial Performance
6.5.7.3. Product Benchmarking
6.5.7.4. Strategic Initiatives
6.5.8. Sebela Pharmaceuticals
6.5.8.1. Overview
6.5.8.2. Financial Performance
6.5.8.3. Product Benchmarking
6.5.8.4. Strategic Initiatives
6.5.9. Phathom Pharmaceuticals, Inc.
6.5.9.1. Overview
6.5.9.2. Financial Performance
6.5.9.3. Product Benchmarking
6.5.9.4. Strategic Initiatives
6.5.10. Camber Pharmaceuticals, Inc.
6.5.10.1. Overview
6.5.10.2. Financial Performance
6.5.10.3. Product Benchmarking
6.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global gastroesophageal reflux disease therapeutics market, by region, 2018 - 2030 (USD Million)
Table 4 Global gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 5 North America gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
Table 6 North America gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 7 U.S. gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 8 Canada gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 9 Mexico gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 10 Europe gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
Table 11 Europe gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 12 UK gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 13 Germany gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 14 France gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 15 Italy gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 16 Spain gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 17 Norway gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 18 Denmark gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 19 Sweden gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 20 Asia Pacific gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
Table 21 Asia Pacific gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 22 Japan gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 23 China gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 24 India gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 25 Australia gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 26 South Korea gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 27 Thailand gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 28 Latin America gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
Table 29 Latin America gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 30 Brazil gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 31 Argentina gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 32 Middle East & Africa Gastroesophageal reflux disease therapeutics market, by country, 2018 - 2030 (USD Million)
Table 33 Middle East & Africa gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 34 South Africa gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 35 Saudi Arabia gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 36 UAE gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
Table 37 Kuwait gastroesophageal reflux disease therapeutics market, by drug type, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Gastroesophageal reflux disease therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Drug type outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Gastroesophageal reflux disease therapeutics market dynamics
Fig. 12 Gastroesophageal reflux disease therapeutics market: Porter’s five forces analysis
Fig. 13 Gastroesophageal reflux disease therapeutics market: PESTLE analysis
Fig. 14 Gastroesophageal reflux disease therapeutics market: Drug type segment dashboard
Fig. 15 Gastroesophageal reflux disease therapeutics market: Drug type market share analysis, 2024 & 2030
Fig. 16 Antacids market, 2018 - 2030 (USD Million)
Fig. 17 H2 receptor blockers market, 2018 - 2030 (USD Million)
Fig. 18 Proton pump inhibitors (PPIs) market, 2018 - 2030 (USD Million)
Fig. 19 Pro-kinetic agents market, 2018 - 2030 (USD Million)
Fig. 20 Gastroesophageal reflux disease therapeutics market revenue, by region
Fig. 21 Regional marketplace: Key takeaways
Fig. 22 Regional marketplace: Key takeaways
Fig. 23 North America gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 24 U.S. country dynamics
Fig. 25 U.S. gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 26 Canada country dynamics
Fig. 27 Canada gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 28 Mexico country dynamics
Fig. 29 Mexico gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 30 Europe gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 31 UK country dynamics
Fig. 32 UK gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 33 Germany country dynamics
Fig. 34 Germany gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 35 France country dynamics
Fig. 36 France gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 37 Italy country dynamics
Fig. 38 Italy gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 39 Spain country dynamics
Fig. 40 Spain gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 41 Norway country dynamics
Fig. 42 Norway gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 43 Sweden country dynamics
Fig. 44 Sweden gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 45 Denmark country dynamics
Fig. 46 Denmark gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 47 Asia Pacific gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 48 Japan country dynamics
Fig. 49 Japan gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 50 China country dynamics
Fig. 51 China gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 52 India country dynamics
Fig. 53 India gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 54 Australia country dynamics
Fig. 55 Australia gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 56 South Korea country dynamics
Fig. 57 South Korea gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 58 Thailand country dynamics
Fig. 59 Thailand gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 60 Latin America gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 61 Brazil country dynamics
Fig. 62 Brazil gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 63 Argentina country dynamics
Fig. 64 Argentina gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 65 MEA gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 66 South Africa country dynamics
Fig. 67 South Africa gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 68 Saudi Arabia country dynamics
Fig. 69 Saudi Arabia gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 70 UAE country dynamics
Fig. 71 UAE gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 72 Kuwait country dynamics
Fig. 73 Kuwait gastroesophageal reflux disease therapeutics market, 2018 - 2030 (USD Million)
Fig. 74 Company categorization
Fig. 75 Company market position analysis
Fig. 76 Strategic framework

Companies Mentioned

  • AstraZeneca
  • Eisai Co., Ltd.
  • GSK plc
  • Takeda Pharmaceutical Company Limited
  • Ironwood
  • Johnson & Johnson Services, Inc.
  • SFJ Pharmaceuticals
  • Sebela Pharmaceuticals
  • Phathom Pharmaceuticals, Inc.
  • Camber Pharmaceuticals, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedDecember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.11 billion
Forecasted Market Value ( USD ) by 2030 $ 5.77 billion
Compound Annual Growth Rate2.0%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Gastroesophageal Reflux Disease Therapeutics Market by Type, Drug Class, Application - Global Forecast 2025-2030 - Product Image

Gastroesophageal Reflux Disease Therapeutics Market by Type, Drug Class, Application - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Gastroesophageal Reflux Disease Therapeutics Global Market Report 2024 - Product Image

Gastroesophageal Reflux Disease Therapeutics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Strategic Business Report - Product Image

Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Gastroesophageal Reflux Disease Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Gastroesophageal Reflux Disease Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 96 Pages
  • Global
From
Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024 - Product Image

Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.